Literature DB >> 12466113

Lens defects and age-related fiber cell degeneration in a mouse model of increased AbetaPP gene dosage in Down syndrome.

Peter H Frederikse1, Xiao-Ou Ren.   

Abstract

Early-onset cataract and Alzheimer's disease occur with high frequency in Down syndrome (trisomy 21), the most common chromosome duplication in human live births. Previously, we used in vivo and lens organ culture models to demonstrate Alzheimer pathophysiology in oxidative stress-related lens degeneration. Currently, well-characterized Alzheimer transgenic mouse models are used to extend these findings. Here, we report on mice carrying a complete copy of a wild-type human AbetaPP (hAbetaPP) gene from the Down syndrome critical region on chromosome 21. hAbetaPP mice produce fiber cell membrane defects similar to those described in human cataracts and increased age-related lens degeneration. hAbetaPP expression and mRNA alternative splicing in human and mouse lens and cornea favor longer, potentially more amyloidogenic forms. Endogenous mouse AbetaPP expression is increased in transgenic lenses, consistent with the cycle of oxidative stress proposed in the mechanism of Alzheimer pathophysiology. Alternative splicing previously designated as neuron-specific occurs in human lens and cornea, and is maintained by hAbetaPP expressed in mouse tissues. These present data implicate AbetaPP in fiber cell formation and in early-onset cataracts in Down syndrome. Finally, our findings provide further support for our hypothesis that Alzheimer pathophysiology contributes to the cataract formation that is increasing in the aging population.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12466113      PMCID: PMC1850926          DOI: 10.1016/s0002-9440(10)64475-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  44 in total

Review 1.  Specific metal-catalysed protein oxidation reactions in chronic degenerative disorders of ageing: focus on Alzheimer's disease and age-related cataracts.

Authors:  A I Bush; L E Goldstein
Journal:  Novartis Found Symp       Date:  2001

Review 2.  Metals and neuroscience.

Authors:  A I Bush
Journal:  Curr Opin Chem Biol       Date:  2000-04       Impact factor: 8.822

3.  A transcriptionally [correction of transcriptively] active complex of APP with Fe65 and histone acetyltransferase Tip60.

Authors:  X Cao; T C Südhof
Journal:  Science       Date:  2001-07-06       Impact factor: 47.728

Review 4.  Oxidative processes in Alzheimer's disease: the role of abeta-metal interactions.

Authors:  T Lynch; R A Cherny; A I Bush
Journal:  Exp Gerontol       Date:  2000-07       Impact factor: 4.032

5.  Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

Authors:  R A Cherny; C S Atwood; M E Xilinas; D N Gray; W D Jones; C A McLean; K J Barnham; I Volitakis; F W Fraser; Y Kim; X Huang; L E Goldstein; R D Moir; J T Lim; K Beyreuther; H Zheng; R E Tanzi; C L Masters; A I Bush
Journal:  Neuron       Date:  2001-06       Impact factor: 17.173

6.  Multilamellar bodies as potential scattering particles in human age-related nuclear cataracts.

Authors:  K O Gilliland; C D Freel; C W Lane; W C Fowler; M J Costello
Journal:  Mol Vis       Date:  2001-06-22       Impact factor: 2.367

7.  Appican expression induces morphological changes in C6 glioma cells and promotes adhesion of neural cells to the extracellular matrix.

Authors:  A Wu; M N Pangalos; S Efthimiopoulos; J Shioi; N K Robakis
Journal:  J Neurosci       Date:  1997-07-01       Impact factor: 6.167

8.  Prion protein expression in mammalian lenses.

Authors:  P H Frederikse; S J Zigler; P N Farnsworth; D A Carper
Journal:  Curr Eye Res       Date:  2000-02       Impact factor: 2.424

9.  Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain.

Authors:  H F Dovey; V John; J P Anderson; L Z Chen; P de Saint Andrieu; L Y Fang; S B Freedman; B Folmer; E Goldbach; E J Holsztynska; K L Hu; K L Johnson-Wood; S L Kennedy; D Kholodenko; J E Knops; L H Latimer; M Lee; Z Liao; I M Lieberburg; R N Motter; L C Mutter; J Nietz; K P Quinn; K L Sacchi; P A Seubert; G M Shopp; E D Thorsett; J S Tung; J Wu; S Yang; C T Yin; D B Schenk; P C May; L D Altstiel; M H Bender; L N Boggs; T C Britton; J C Clemens; D L Czilli; D K Dieckman-McGinty; J J Droste; K S Fuson; B D Gitter; P A Hyslop; E M Johnstone; W Y Li; S P Little; T E Mabry; F D Miller; J E Audia
Journal:  J Neurochem       Date:  2001-01       Impact factor: 5.372

10.  Developmental regulation of amyloid precursor protein at the neuromuscular junction in mouse skeletal muscle.

Authors:  M Akaaboune; B Allinquant; H Farza; K Roy; R Magoul; M Fiszman; B W Festoff; D Hantaï
Journal:  Mol Cell Neurosci       Date:  2000-04       Impact factor: 4.314

View more
  18 in total

1.  miRNA and Dicer in the mammalian lens: expression of brain-specific miRNAs in the lens.

Authors:  Peter H Frederikse; Robert Donnelly; Lukasz M Partyka
Journal:  Histochem Cell Biol       Date:  2006-01-06       Impact factor: 4.304

2.  Beta-amyloid deposition and functional impairment in the retina of the APPswe/PS1DeltaE9 transgenic mouse model of Alzheimer's disease.

Authors:  Sylvia E Perez; Stephen Lumayag; Beatrix Kovacs; Elliott J Mufson; Shunbin Xu
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-09-12       Impact factor: 4.799

Review 3.  At the interface of sensory and motor dysfunctions and Alzheimer's disease.

Authors:  Mark W Albers; Grover C Gilmore; Jeffrey Kaye; Claire Murphy; Arthur Wingfield; David A Bennett; Adam L Boxer; Aron S Buchman; Karen J Cruickshanks; Davangere P Devanand; Charles J Duffy; Christine M Gall; George A Gates; Ann-Charlotte Granholm; Takao Hensch; Roee Holtzer; Bradley T Hyman; Frank R Lin; Ann C McKee; John C Morris; Ronald C Petersen; Lisa C Silbert; Robert G Struble; John Q Trojanowski; Joe Verghese; Donald A Wilson; Shunbin Xu; Li I Zhang
Journal:  Alzheimers Dement       Date:  2014-07-09       Impact factor: 21.566

4.  FE65 and FE65L1 amyloid precursor protein-binding protein compound null mice display adult-onset cataract and muscle weakness.

Authors:  Jaehong Suh; Juliet A Moncaster; Lirong Wang; Imran Hafeez; Joachim Herz; Rudolph E Tanzi; Lee E Goldstein; Suzanne Y Guénette
Journal:  FASEB J       Date:  2015-03-10       Impact factor: 5.191

5.  Clinicopathological study of bilateral developmental cataracts diagnosed in utero.

Authors:  Fiona Roberts; Stephen Wisdom; Allan G Howatson; Stuart Imrie
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2005-07-19       Impact factor: 3.117

6.  A test of lens opacity as an indicator of preclinical Alzheimer Disease.

Authors:  Ling Bei; Ying-Bo Shui; Fang Bai; Suzanne K Nelson; Gregory P Van Stavern; David C Beebe
Journal:  Exp Eye Res       Date:  2015-03-13       Impact factor: 3.467

7.  Differential accumulation of secreted AbetaPP metabolites in ocular fluids.

Authors:  Annamalai Prakasam; Anusuya Muthuswamy; Zsolt Ablonczy; Nigel H Greig; Abdul Fauq; Kosagisharaf Jagannatha Rao; Miguel A Pappolla; Kumar Sambamurti
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

8.  Amyloid-peptide vaccinations reduce {beta}-amyloid plaques but exacerbate vascular deposition and inflammation in the retina of Alzheimer's transgenic mice.

Authors:  Bingqian Liu; Suhail Rasool; Zhikuan Yang; Charles G Glabe; Steven S Schreiber; Jian Ge; Zhiqun Tan
Journal:  Am J Pathol       Date:  2009-10-15       Impact factor: 4.307

Review 9.  Peripheral Biomarkers for Early Detection of Alzheimer's and Parkinson's Diseases.

Authors:  Thein Than Htike; Sachin Mishra; Sundramurthy Kumar; Parasuraman Padmanabhan; Balázs Gulyás
Journal:  Mol Neurobiol       Date:  2018-07-14       Impact factor: 5.590

10.  Cataracts in transgenic mice caused by a human papillomavirus type 18 E7 oncogene driven by KRT1-14.

Authors:  Shinje Ghim; A Bennett Jenson; Jason A Bubier; Kathleen A Silva; Richard S Smith; John P Sundberg
Journal:  Exp Mol Pathol       Date:  2008-08-06       Impact factor: 3.362

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.